drugset / Trial / NCT03310125

Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)

NCT03310125 ↗

RandomizedParallel-groupTriple-blindPrevention

Summary

The prevention of perioperative atrial fibrillation (AF) and myocardial injury after non-cardiac surgery (MINS) has the potential to reduce mortality, stroke, and hospital stays in patients undergoing major thoracic surgery. Data from cardiac surgery patients suggest that prevention of perioperative atrial fibrillation using an anti-inflammatory agent, such as colchicine, is feasible. The COP-AF trial will assess whether the administration of oral colchicine will reduce the incidence of perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery.

Timeline

Start
2018-02-14
Primary completion
2023-07-26
Completion
2023-07-26

Outcome

Missed primary endpoint

paper administration of colchicine did not significantly reduce the incidence of clinically important atrial fibrillation or MINS PMID 37640035 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Colchicine Small molecule 0.5 mg Oral